Research Article

SET8 expression is associated with overall survival in gastric cancer

Published: December 02, 2015
Genet. Mol. Res. 14 (4) : 15609-15615 DOI: https://doi.org/10.4238/2015.December.1.12
Cite this Article:
X.L. Shi, Z.J. Guo, X.L. Wang, X.L. Liu, G.F. Shi (2015). SET8 expression is associated with overall survival in gastric cancer. Genet. Mol. Res. 14(4): 15609-15615. https://doi.org/10.4238/2015.December.1.12
786 views

Abstract

SET8, a member of the SET domain-containing methyl­transferase, has been implicated in various biological processes. In this study, SET8 was immunostained in 100 samples of gastric cancer tis­sues and semi-quantified using the HSCORE method to determine the predictive value of SET8 expression levels for gastric cancer outcome. The relationship between SET8 expression and the 5-year survival rate of gastric cancer patients was assessed. High expression of SET8 was asso­ciated with a shorter survival time in gastric cancer patients, and the level of SET8 expression was found to be an independent predictor of gastric cancer outcome (relative risk = 1.939; 95% confidence interval = 1.025-3.668; P = 0.042). Analysis of SET8 levels may help in the identification of patient subgroups that are at high risk for poor disease outcomes.

SET8, a member of the SET domain-containing methyl­transferase, has been implicated in various biological processes. In this study, SET8 was immunostained in 100 samples of gastric cancer tis­sues and semi-quantified using the HSCORE method to determine the predictive value of SET8 expression levels for gastric cancer outcome. The relationship between SET8 expression and the 5-year survival rate of gastric cancer patients was assessed. High expression of SET8 was asso­ciated with a shorter survival time in gastric cancer patients, and the level of SET8 expression was found to be an independent predictor of gastric cancer outcome (relative risk = 1.939; 95% confidence interval = 1.025-3.668; P = 0.042). Analysis of SET8 levels may help in the identification of patient subgroups that are at high risk for poor disease outcomes.